var data={"title":"Docetaxel: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Docetaxel: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6060?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">see &quot;Docetaxel: Drug information&quot;</a> and <a href=\"topic.htm?path=docetaxel-patient-drug-information\" class=\"drug drug_patient\">see &quot;Docetaxel: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708706\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Increased mortality:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The incidence of treatment-related mortality associated with docetaxel is increased in patients with abnormal liver function, patients receiving higher doses, and patients with non&ndash;small cell lung cancer and a history of prior treatment with platinum-based chemotherapy who receive docetaxel as a single agent at a dose of 100 mg/m<sup>2</sup>.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatic function impairment:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Do not give docetaxel to patients with bilirubin above the upper limit of normal (ULN), or patients with AST and/or ALT above 1.5 times the ULN concomitant with alkaline phosphatase above 2.5 times the ULN. Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of grade 4 neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase above 1.5 times the ULN also had a higher rate of febrile grade 4 neutropenia but did not have an increased incidence of toxic death. Obtain bilirubin, AST or ALT, and alkaline phosphatase values prior to each cycle of docetaxel therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neutropenia:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Do not give docetaxel therapy to patients with neutrophil counts below 1,500 cells/mm<sup>3</sup>. In order to monitor the occurrence of neutropenia, which may be severe and result in infection, perform frequent blood cell counts on all patients receiving docetaxel.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hypersensitivity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe hypersensitivity reactions, characterized by general rash/erythema, hypotension, and/or bronchospasm, or, very rarely, fatal anaphylaxis, have been reported in patients who received a 3-day dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the docetaxel infusion and administration of appropriate therapy. Do not give docetaxel to patients who have a history of severe hypersensitivity reactions to docetaxel or to other drugs formulated with polysorbate 80.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Fluid retention:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe fluid retention occurred in 6.5% of patients despite the use of a 3-day dexamethasone premedication regimen. It was characterized by 1 or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162052\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Docefrez [DSC];</li>\n      <li>Taxotere</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162053\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Docetaxel for Injection;</li>\n      <li>Docetaxel Injection;</li>\n      <li>Taxotere</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1009498\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antimicrotubular</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Taxane Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1009534\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">see &quot;Docetaxel: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Dose, frequency, number of doses, and start date may vary by protocol and treatment phase. Refer to individual protocols: <b>Note:</b> Premedicate with corticosteroids, beginning the day before docetaxel administration (administer corticosteroids for 1 to 3 days), to reduce the severity of hypersensitivity reactions and pulmonary/peripheral edema. Docetaxel is associated with a low emetic potential (Dupuis 2011); antiemetics are recommended to prevent nausea and vomiting (Dupuis 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sarcomas,</b> <b>Ewing Sarcoma; osteosarcoma (recurrent or progressive):</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Mora 2009</i>: G + D regimen: Children and Adolescents: IV: 100 mg/m<sup>2</sup> over 2 to 4 hours on Day 8 of a 21-day cycle in combination with gemcitabine</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Rapkin 2012</i>: GEMDOX regimen:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: IV: 2.5 mg/kg over 1 hour on Day 8 of a 21-day cycle in combination with gemcitabine</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents: IV: 75 mg/m<sup>2</sup> over 1 hour on Day 8 of a 21-day cycle in combination with gemcitabine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatoblastoma (refractory or relapsed): </b>Limited data available, case-series reports (George 2012): Infants and Children:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patient weight &lt;10 kg: IV: 3.3 mg/kg as a 1-hour infusion every 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patient weight &gt;10 kg: IV: 100 mg/m<sup>2</sup> given as a 1-hour infusion every 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Breast cancer:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Locally advanced or metastatic: 60 to 100 mg/m<sup>2</sup> every 3 weeks as a single agent</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Operable, node-positive (adjuvant treatment): 75 mg/m<sup>2</sup> every 3 weeks for 6 courses (in combination with doxorubicin and cyclophosphamide)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Non-small cell lung cancer:</b> IV: 75 mg/m<sup>2</sup> every 3 weeks (as monotherapy or in combination with cisplatin)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prostate cancer:</b> IV: 75 mg/m<sup>2</sup> every 3 weeks (in combination with prednisone)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastric adenocarcinoma:</b> IV: 75 mg/m<sup>2</sup> every 3 weeks (in combination with cisplatin and fluorouracil)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Head and neck cancer:</b> IV: 75 mg/m<sup>2</sup> every 3 weeks (in combination with cisplatin and fluorouracil) for 3 or 4 cycles, followed by radiation therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment for concomitant CYP3A4 inhibitors:</b> Specific pediatric recommendations are lacking; based on experience in adult patients: Avoid the concomitant use of strong CYP3A4 inhibitors with docetaxel. If concomitant use of a strong CYP3A4 inhibitor cannot be avoided, consider reducing the docetaxel dose by 50% (based on limited pharmacokinetic data).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult: <b>Note:</b> Toxicity includes febrile neutropenia, neutrophils &le;500/mm<sup>3</sup> for &gt;1 week, severe or cumulative cutaneous reactions; in non-small cell lung cancer, this may also include platelets &lt;25,000/mm<sup>3</sup> and other grade 3/4 nonhematologic toxicities.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Breast cancer (single agent):</b> Patients dosed initially at 100 mg/m<sup>2 </sup>(adult); reduce dose to 75 mg/m<sup>2</sup> (adult); <b>Note:</b> If the patient continues to experience these adverse reactions, the dosage should be reduced to 55 mg/m<sup>2</sup> (adult) or therapy should be discontinued; discontinue for peripheral neuropathy &ge; grade 3. Patients initiated at 60 mg/m<sup>2 </sup>(adult) who do not develop toxicity may tolerate higher doses.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Breast cancer, adjuvant treatment (combination chemotherapy):</b> TAC regimen should be administered when neutrophils are &ge;1,500/mm<sup>3</sup>. Patients experiencing febrile neutropenia should receive G-CSF in all subsequent cycles. Patients with persistent febrile neutropenia (while on G-CSF), patients experiencing severe/cumulative cutaneous reactions, moderate neurosensory effects (signs/symptoms) or grade 3 or 4 stomatitis should receive a reduced dose (60 mg/m<sup>2</sup> in adults) of docetaxel. Discontinue therapy with persistent toxicities after dosage reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Non-small cell lung cancer:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Monotherapy: Patients dosed initially at 75 mg/m<sup>2 </sup>(adult) should have dose held until toxicity is resolved, then resume at 55 mg/m<sup>2 </sup>(adult); discontinue for peripheral neuropathy &ge; grade 3</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Combination therapy (with cisplatin): Patients dosed initially at 75 mg/m<sup>2 </sup>(adult) should have the docetaxel dosage reduced to 65 mg/m<sup>2</sup> (adult) in subsequent cycles; if further adjustment is required, dosage may be reduced to 50 mg/m<sup>2 </sup>(adult)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Prostate cancer:</b> Reduce dose to 60 mg/m<sup>2</sup> (adult); discontinue therapy if toxicities persist at lower dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Gastric cancer, head and neck cancer:</b> <b>Note:</b> Cisplatin may require dose reductions/therapy delays for peripheral neuropathy, ototoxicity, and/or nephrotoxicity. Patients experiencing febrile neutropenia, documented infection with neutropenia or neutropenia &gt;7 days should receive G-CSF in all subsequent cycles. For neutropenic complications despite G-CSF use, further reduce dose to 60 mg/m<sup>2 </sup>(adult). Dosing with neutropenic complications in subsequent cycles should be further reduced to 45 mg/m<sup>2 </sup>(adult). Patients who experience grade 4 thrombocytopenia should receive a dose reduction from 75 mg/m<sup>2</sup> to 60 mg/m<sup>2 </sup> (adult dosing). Discontinue therapy for persistent toxicities.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Gastrointestinal toxicity for docetaxel in combination with cisplatin and fluorouracil for treatment of gastric cancer or head and neck cancer:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Diarrhea, grade 3:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">First episode: Reduce fluorouracil dose by 20%</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Second episode: Reduce docetaxel dose by 20%</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Diarrhea, grade 4:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">First episode: Reduce fluorouracil and docetaxel doses by 20%</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Second episode: Discontinue treatment</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Stomatitis, grade 3:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">First episode: Reduce fluorouracil dose by 20%</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Second episode: Discontinue fluorouracil for all subsequent cycles</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Third episode: Reduce docetaxel dose by 20%</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Stomatitis, grade 4:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">First episode: Discontinue fluorouracil for all subsequent cycles</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Second episode: Reduce docetaxel dose by 20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults: Renal excretion is minimal; therefore, the need for dosage adjustments for renal dysfunction is unlikely (Janus 2010; Li 2007). Not removed by hemodialysis; may be administered before or after hemodialysis (Janus 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Total bilirubin greater than the ULN, or AST/ALT &gt;1.5 times ULN concomitant with alkaline phosphatase &gt;2.5 times ULN: Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hepatic impairment dosing adjustment specific for gastric or head and neck cancer:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">AST/ALT &gt;2.5 to &le;5 times ULN and alkaline phosphatase &le;2.5 times ULN: Administer 80% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">AST/ALT &gt;1.5 to &le;5 times ULN and alkaline phosphatase &gt;2.5 to &le;5 times ULN: Administer 80% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">AST/ALT &gt;5 times ULN and /or alkaline phosphatase &gt;5 times ULN: Discontinue docetaxel</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The following guidelines have been used by some clinicians (Floyd 2006):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AST/ALT 1.6 to 6 times ULN: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AST/ALT &gt;6 times ULN: Use clinical judgment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162028\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Concentrate, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Taxotere: 20 mg/mL (1 mL); 80 mg/4 mL (4 mL) [contains alcohol, usp, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg/mL (1 mL); 80 mg/4 mL (4 mL); 160 mg/8 mL (8 mL); 200 mg/10 mL (10 mL); 20 mg/0.5 mL (0.5 mL); 80 mg/2 mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Concentrate, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg/mL (1 mL); 80 mg/4 mL (4 mL); 140 mg/7 mL (7 mL [DSC]); 160 mg/8 mL (8 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg/2 mL (2 mL); 80 mg/8 mL (8 mL); 160 mg/16 mL (16 mL); 200 mg/20 mL (20 mL [DSC]); 20 mg/mL (1 mL); 80 mg/4 mL (4 mL); 160 mg/8 mL (8 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Docefrez: 20 mg (1 ea [DSC]); 80 mg (1 ea [DSC]) [contains alcohol, usp, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162014\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46044272\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">see &quot;Docetaxel: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Non-alcohol formulation (Eagle/Teikuku pharmaceuticals): Solution, Intravenous [alcohol-free]: Generic: 20 mg/mL (1 mL; single-dose vial); 80 mg/4 mL (4 mL multi-dose vial); 160 mg/8 mL (8 mL; multi-dose vial)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1009541\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Administer as an IV infusion over 1 hour through nonsorbing polyethylene-lined (non-DEHP) tubing; in-line filter is not necessary (the use of a filter during administration is not recommended by the manufacturer). Infusion should be completed within 4 hours of preparation. <b>Note:</b> Premedication with corticosteroids for 3 days, beginning the day before docetaxel administration, is recommended to prevent hypersensitivity reactions and pulmonary/peripheral edema. Some docetaxel formulations contain alcohol (content varies by formulation); use with caution in patients for whom alcohol intake should be avoided or minimized.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Irritant with vesicant-like properties; avoid extravasation. Assure proper needle or catheter position prior to administration. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Information conflicts regarding the use of warm or cold compresses (P&eacute;rez Fidalgo 2012; Polovich 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130975\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).  </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162045\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Storage and stability may vary by manufacturer, refer to specific prescribing information. Follow USP 797 recommendations for beyond use dates based on the level of risk for preparation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Docetaxel 10 mg/mL: Store intact vials between 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F) (actual recommendations may vary by generic manufacturer; consult manufacturer&rsquo;s labeling). Protect from bright light. Freezing does not adversely affect the product. Multi-use vials (80 mg/8 mL and 160 mg/16 mL) are stable for up to 28 days after first entry when stored between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) and protected from light. Solutions diluted for infusion should be used within 4 hours of preparation, including infusion time.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Docetaxel 20 mg/mL concentrate/solution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Taxotere: Store intact vials between 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F). Protect from bright light. Freezing does not adversely affect the product. Solutions diluted for infusion in D5W or NS in non-PVC containers should be used within 6 hours of preparation, including infusion time, when stored between 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F) or within 48 hours when stored between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic formulations: Store intact vials between 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F). Protect from light. Freezing does not adversely affect the product. Multi-use vials are stable for up to 28 days after first entry when stored between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) and protected from light. Solutions diluted for infusion in D5W or NS should be used within 6 hours of preparation, including infusion time. Actual recommendations may vary by generic manufacturer; consult manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-alcohol formulation: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light. After the first use and following multiple needle entries and withdrawals, multi-use vials (80 mg/4 mL and 160 mg/8 mL) are stable for up to 28 days when stored between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) and protected from light. Solutions diluted for infusion in NS or D5W are stable for 24 hours when stored between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Docetaxel lyophilized powder (Docefrez): Store intact vials between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light. Allow vials (and provided diluent) to stand at room temperature for 5 minutes prior to reconstitution. After reconstitution, may be stored refrigerated or at room temperature for up to 8 hours. Solutions diluted for infusion in D5W or NS should be used within 6 hours of preparation, including infusion time. According to the manufacturer, physical and chemical in-use stability of the infusion solution (prepared as recommended) has been demonstrated in non-PVC bags up to 48 hours when stored between 2&deg;C and 8&deg;C (36&deg;F and 46&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Two-vial formulation</b>\n      <b>\n        <i> (generic; concentrate plus diluent formulation):</i></b> Reconstituted solutions of the two-vial formulation are stable in the vial for 8 hours at room temperature or under refrigeration. Solutions diluted for infusion in NS or D5W in polyolefin containers should be used within 4 hours of preparation, including infusion time.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1009499\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of breast cancer (locally advanced/metastatic or adjuvant treatment of operable node-positive); locally advanced or metastatic non-small cell lung cancer (NSCLC); and hormone refractory, metastatic prostate cancer (Docefrez, Taxotere: FDA approved in adults); advanced gastric adenocarcinoma; locally advanced squamous cell head and neck cancer (Taxotere: FDA approved in adults); has also been used in the treatment of  soft tissue sarcoma; Ewing sarcoma, osteosarcoma, and unknown primary adenocarcinoma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162103\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DOCEtaxel may be confused with cabazitaxel, PACLitaxel</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Taxotere may be confused with Taxol</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Multiple concentrations: Docetaxel is available as a one-vial formulation at concentrations of 10 mg/mL (generic formulation) and 20 mg/mL (concentrate/solution; Taxotere or non-alcohol generic formulation), and as a lyophilized powder (Docefrez) which is reconstituted (with provided diluent) to 20 mg/0.8 mL (20 mg vial) or 24 mg/mL (80 mg vial). Docetaxel was previously available as a two-vial formulation (a concentrated docetaxel solution vial and a diluent vial) resulting in a reconstituted concentration of 10 mg/mL. The two-vial formulation has been discontinued by the Taxotere manufacturer (available generically). Admixture errors have occurred due to the availability of various docetaxel concentrations. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162099\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Percentages reported for docetaxel monotherapy; frequency may vary depending on diagnosis, dose, liver function, prior treatment, and premedication.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Decreased left ventricular ejection fraction, hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Central nervous system toxicity (including neuropathy), peripheral motor neuropathy (severe; mainly distal extremity weakness)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, dermatological reaction, nail disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Fluid retention (includes edema and effusion; dose dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, dysgeusia, nausea, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia (dose dependent), febrile neutropenia (dose dependent), leukopenia, neutropenia (nadir [median]: 7 days, duration [severe neutropenia]: 7 days; dose dependent), thrombocytopenia (dose dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum alkaline phosphatase, increased serum bilirubin, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection (dose dependent), severe infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Infusion site reactions (including hyperpigmentation, inflammation, redness, dryness, phlebitis, extravasation, swelling of the vein)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia, neuromuscular reaction, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Pulmonary reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute myelocytic leukemia, acute hepatic failure (Morgan 2011), acute respiratory distress, alopecia (permanent), anaphylactic shock, anorexia, ascites, atrial fibrillation, atrial flutter, back pain, bronchospasm, cardiac arrhythmia, cardiac tamponade, chest pain, chest tightness, chills, colitis, confusion, conjunctivitis, constipation, cystoid macular edema, deep vein thrombosis, dehydration, disease of the lacrimal apparatus (duct obstruction), disseminated intravascular coagulation, drug fever, duodenal ulcer, dyspnea, ECG abnormality, epiphora (more common with weekly administration [Kintzel 2006]), erythema multiforme, esophagitis, flushing, gastrointestinal hemorrhage, gastrointestinal obstruction, gastrointestinal perforation, hearing loss, hemorrhagic diathesis, hepatitis, hypertension, hyponatremia, intestinal obstruction, interstitial pulmonary disease, ischemic colitis, localized erythema of the extremities, loss of consciousness (transient), lymphedema (peripheral), multiorgan failure, myelodysplastic syndrome, myocardial infarction, neutropenic enterocolitis, ototoxicity, palmar-plantar erythrodysesthesia, pneumonia, pneumonitis, pruritus, pulmonary edema, pulmonary embolism, pulmonary fibrosis, radiation pneumonitis, radiation recall phenomenon, renal failure, renal insufficiency, respiratory failure, seizure, sepsis, sinus tachycardia, skin changes (scleroderma-like), skin rash, Stevens-Johnson syndrome, subacute cutaneous lupus erythematosus, syncope, tachycardia, thrombophlebitis, toxic epidermal necrolysis, unstable angina pectoris, visual disturbance (transient)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162034\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe hypersensitivity to docetaxel or any component of the formulation; severe hypersensitivity to other medications containing polysorbate 80; neutrophil count &lt;1,500/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Severe hepatic impairment; pregnancy; breastfeeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162018\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: Patients with an absolute neutrophil count &lt;1,500/mm<sup>3</sup> should not receive docetaxel. Monitor blood counts frequently to monitor for neutropenia (which may be severe and result in infection).</b> The dose-limiting toxicity is neutropenia. Platelets should recover to &gt;100,000/mm<sup>3</sup> prior to treatment. Patients with increased liver function tests experienced more episodes of neutropenia with a greater number of severe infections; monitor liver function tests frequently. Hematologic toxicity may require dose reduction or therapy discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous reactions: Cutaneous reactions, including erythema (with edema) and desquamation, have been reported; may require dose reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Docetaxel is an irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid retention: <b> [US Boxed Warning]: Severe fluid retention, characterized by pleural effusion (requiring immediate drainage), ascites with pronounced abdominal distention, peripheral edema (poorly tolerated), dyspnea at rest, cardiac tamponade, generalized edema, and weight gain, has been reported (despite the use of premedication with 3 days of dexamethasone).</b> Fluid retention may begin as lower extremity peripheral edema and become generalized with a median weight gain of 2 kg. In patients with breast cancer, the median cumulative dose to onset of moderate or severe fluid retention was 819 mg/m<sup>2</sup>; fluid retention resolves in a median of 16 weeks after discontinuation. Patients should be premedicated with a corticosteroid (starting 1 day prior to administration) to reduce the incidence and severity of fluid retention. Closely monitor patients with existing effusions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: <b>[US Boxed Warning]: Severe hypersensitivity reactions, characterized by generalized rash/erythema, hypotension, bronchospasms, or rare anaphylaxis may occur (may be fatal; has occurred in patients receiving a 3-day corticosteroid premedication). Hypersensitivity reactions require immediate discontinuation of the docetaxel infusion and administration of appropriate therapy. Do not administer to patients with a history of severe hypersensitivity to docetaxel or polysorbate 80. </b> Minor reactions including flushing or localized skin reactions may also occur. Observe for hypersensitivity, especially with the first 2 infusions. Discontinue for severe reactions; do not rechallenge if severe. Patients should be premedicated with a corticosteroid (starting 1 day prior to administration) to prevent or reduce the severity of hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurosensory symptoms: Dosage adjustment is recommended with severe neurosensory symptoms (paresthesia, dysesthesia, pain); persistent symptoms may require discontinuation. Reversal of symptoms may be delayed after discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular adverse effects: Cystoid macular edema (CME) has been reported; if vision impairment occurs, a prompt comprehensive ophthalmic exam is recommended. If CME is diagnosed, initiate appropriate CME management and discontinue docetaxel (consider non-taxane treatments). In a study of patients receiving docetaxel for the adjuvant treatment of breast cancer, a majority of patients experienced tearing, which occurred in patients with and without lacrimal duct obstruction at baseline. Onset was generally after cycle 1, but subsided in most patients within 4 months after therapy completion (Chan 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancies: Treatment-related acute myeloid leukemia or myelodysplasia occurred in patients receiving docetaxel in combination with anthracyclines and/or cyclophosphamide.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Treatment-related mortality: <b>[US Boxed Warning]: Patients with abnormal liver function, those receiving higher doses, and patients with non&ndash;small cell lung cancer and a history of prior treatment with platinum derivatives who receive single-agent docetaxel at a dose of 100 mg/m<sup>2</sup> are at higher risk for treatment-related mortality.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weakness: Fatigue and weakness (may be severe) have been reported; symptoms may last a few days up to several weeks. In patients with progressive disease, weakness may be associated with a decrease in performance status.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: In a scientific statement from the American Heart Association, docetaxel has been determined to be an agent that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: <b>[US Boxed Warning]: Avoid use in patients with bilirubin exceeding upper limit of normal (ULN) or AST and/or ALT &gt;1.5 times ULN in conjunction with alkaline phosphatase &gt;2.5 times ULN. Patients with bilirubin elevations or abnormal transaminases (with concurrent abnormal alkaline phosphatase) are at increased risk for grade 4 neutropenia, neutropenic fever, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated transaminase elevations &gt;1.5 times ULN also had a higher rate of grade 4 neutropenic fever, although no increased incidence of toxic death. Monitor bilirubin, AST or ALT, and alkaline phosphatase prior to each docetaxel cycle.</b> The alcohol content of the docetaxel formulation should be taken into account when administering to patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Alcohol content: Some docetaxel formulations contain alcohol (content varies by formulation), which may affect the central nervous system and cause symptoms of alcohol intoxication. Consider alcohol content and use with caution in patients for whom alcohol intake should be avoided or minimized. Patients should avoid driving or operating machinery immediately after the infusion. An FDA-approved non-alcohol generic formulation (20 mg/mL) is available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Premedication: Premedication with oral corticosteroids is recommended to decrease the incidence and severity of fluid retention and severity of hypersensitivity reactions. The manufacturer recommends dexamethasone 16 mg/day (8 mg twice daily) orally for 3 days, starting the day before docetaxel administration; for prostate cancer, when prednisone is part of the antineoplastic regimen, dexamethasone 8 mg orally is administered at 12 hours, 3 hours, and 1 hour prior to docetaxel.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162087\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162022\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13011&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Anthracyclines: Taxane Derivatives may enhance the adverse/toxic effect of Anthracyclines. Taxane Derivatives may increase the serum concentration of Anthracyclines. Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of DOCEtaxel. Management: Avoid the concomitant use of docetaxel and strong CYP3A4 inhibitors when possible. If combined use is unavoidable, consider a 50% docetaxel dose reduction and monitor for increased docetaxel toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: May increase the serum concentration of DOCEtaxel. Management: Avoid this combination whenever possible.  If this combination must be used, consider using a reduced docetaxel dose, and/or increase monitoring for evidence of serious docetaxel toxicity (e.g., neutropenia, mucositis, etc.).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Platinum Derivatives: May enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SORAfenib: May increase the serum concentration of DOCEtaxel.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162024\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162037\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. An <i>ex vivo</i> human placenta perfusion model illustrated that docetaxel crossed the placenta at term. Placental transfer was low and affected by the presence of albumin; higher albumin concentrations resulted in lower docetaxel placental transfer (Berveiller 2012). Some pharmacokinetic properties of docetaxel may be altered in pregnant women (van Hasselt 2014). Women of childbearing potential should avoid becoming pregnant during therapy. A pregnancy registry is available for all cancers diagnosed during pregnancy at Cooper Health (877-635-4499).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1009544\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, liver function tests, bilirubin, alkaline phosphatase, renal function; monitor for hypersensitivity reactions, neurosensory symptoms, gastrointestinal toxicity (eg, diarrhea, stomatitis), cutaneous reactions, fluid retention, epiphora, and canalicular stenosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162017\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Docetaxel promotes the assembly of microtubules from tubulin dimers, and inhibits the depolymerization of tubulin which stabilizes microtubules in the cell. This results in inhibition of DNA, RNA, and protein synthesis. Most activity occurs during the M phase of the cell cycle.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162033\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">Exhibits linear pharmacokinetics at the recommended dosage range </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Extensive extravascular distribution and/or tissue binding; V<sub>dss</sub>: 113 L (mean steady state) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~94% to 97%, primarily to alpha<sub>1</sub>-acid glycoprotein, albumin, and lipoproteins </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; oxidation via CYP3A4 to metabolites </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: ~11 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (~75%, &lt;8% as unchanged drug); urine (~6%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1009550\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Premedication with oral corticosteroids is recommended to decrease the incidence and severity of fluid retention and severity of hypersensitivity reactions. The manufacturer recommends dexamethasone 16 mg (8 mg twice daily) orally for 3 days. In one pediatric clinical trial, dexamethasone  3 mg/m<sup>2</sup> orally or IV every 6 hours for 2 doses, starting 12 hours before docetaxel administration has been described (Zwerdling 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323117\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Concentrate</b> (DOCEtaxel Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/0.5 mL (0.5 mL): $365.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (1 mL): $240.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg/2 mL (2 mL): $1,460.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg/4 mL (4 mL): $960.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">160 mg/8 mL (8 mL): $1,920.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/10 mL (10 mL): $840.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Concentrate</b> (Taxotere Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (1 mL): $690.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg/4 mL (4 mL): $2,762.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (DOCEtaxel (Non-Alcohol) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (1 mL): $258.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg/4 mL (4 mL): $1,032.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">160 mg/8 mL (8 mL): $2,064.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (DOCEtaxel Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/2 mL (2 mL): $82.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg/8 mL (8 mL): $330.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">160 mg/16 mL (16 mL): $660.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869377\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Asodoc (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Belotaxel (KR);</li>\n      <li>Bestdocel (VN);</li>\n      <li>Brexel (ID);</li>\n      <li>Camitotic (LV);</li>\n      <li>Daxotel (ID, PH, SG, TH, VE, ZW);</li>\n      <li>Decexan (LK);</li>\n      <li>Dexotel (IN);</li>\n      <li>Docetax (BD, IN, PH);</li>\n      <li>Docexan (BD);</li>\n      <li>Dolectran (EC);</li>\n      <li>Doletran (PY);</li>\n      <li>Donataxel (EC);</li>\n      <li>Dotaxel (KR);</li>\n      <li>Dotsetaks (UA);</li>\n      <li>Doxecal (PH);</li>\n      <li>Doxestad (PH);</li>\n      <li>Doxetal (JO);</li>\n      <li>Doxetasan (ID, LK);</li>\n      <li>Hentaxel (PH);</li>\n      <li>Isotera (TW);</li>\n      <li>Monotaxel (KR);</li>\n      <li>Newtaxel-A (PH);</li>\n      <li>Newtaxell (VN);</li>\n      <li>Novotaxel (LK);</li>\n      <li>Oncodocel (BR, CO);</li>\n      <li>Oncotaxel (AU, SG, TH);</li>\n      <li>Pacancer (KR);</li>\n      <li>Qvidadotax (ES);</li>\n      <li>Taceedo (ET, PH);</li>\n      <li>Taxanit (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Taxanit RTU (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Taxelo (KR);</li>\n      <li>Taxomed (PE);</li>\n      <li>Taxotere (AE, AR, AT, AU, BB, BD, BE, BF, BG, BH, BJ, BO, BR, CH, CI, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, HK, HN, HR, HU, ID, IE, IL, IS, IT, JO, JP, KE, KR, KW, LB, LR, LT, LU, LV, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NZ, PA, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SV, TH, TN, TR, TW, TZ, UA, UG, UY, VE, VN, ZA, ZM, ZW);</li>\n      <li>Taxozen (KR);</li>\n      <li>Tedocad (BG);</li>\n      <li>Texot (AR, LB, UY);</li>\n      <li>Tyxan (TW);</li>\n      <li>Vexdo (PH);</li>\n      <li>Zytax (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berveiller P, Vinot C, Mir O, et al, &quot;Comparative Transplacental Transfer of Taxanes Using the Human Perfused Cotyledon Placental Model,&quot; <i>Am J Obstet Gynecol</i>, 2012, 207(6):514.e1-514.e7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/docetaxel-pediatric-drug-information/abstract-text/23174392/pubmed\" target=\"_blank\" id=\"23174392\">23174392</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chan A, Su C, de Boer RH, et al. Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy. <i>J Clin Oncol</i>. 2013;31(17):2123-2127.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/docetaxel-pediatric-drug-information/abstract-text/23650421/pubmed\" target=\"_blank\" id=\"23650421\">23650421</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clarke SJ and Rivory LP, &quot;Clinical Pharmacokinetics of Docetaxel,&quot; <i>Clin Pharmacokinet</i>, 1999, 36(2):99-114.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/docetaxel-pediatric-drug-information/abstract-text/10092957/pubmed\" target=\"_blank\" id=\"10092957\">10092957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patient. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/docetaxel-pediatric-drug-information/abstract-text/23512831 /pubmed\" target=\"_blank\" id=\"23512831 \">23512831 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/docetaxel-pediatric-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd J, Mirza I, Sachs B, et al, &quot;Hepatotoxicity of Chemotherapy,&quot; <i>Semin Oncol</i>, 2006, 33(1):50-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/docetaxel-pediatric-drug-information/abstract-text/16473644/pubmed\" target=\"_blank\" id=\"16473644\">16473644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    George SL, Broster S, Chisholm JC, Brock P. Docetaxel in the treatment of children with refractory or relapsed hepatoblastoma. <i>J Pediatr Hematol Oncol</i>. 2012;34(7):e295-297.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/docetaxel-pediatric-drug-information/abstract-text/22469940/pubmed\" target=\"_blank\" id=\"22469940\">22469940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/docetaxel-pediatric-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Janus N, Thariat J, Boulanger H, et al, &quot;Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,&quot; <i>Ann Oncol</i>, 2010, 21(7):1395-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/docetaxel-pediatric-drug-information/abstract-text/20118214/pubmed\" target=\"_blank\" id=\"20118214\">20118214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuo C, Kent PM, Logan AD, et al. Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: a single-center experience. <i>Pediatr Blood Cancer</i>. 2016;00:1-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/docetaxel-pediatric-drug-information/abstract-text/20118214/pubmed\" target=\"_blank\" id=\"20118214\">20118214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li YF, Fu S, Hu W, et al, &quot;Systemic Anticancer Therapy in Gynecological Cancer Patients With Renal Dysfunction,&quot;<i> Int J Gynecol Cancer</i>, 2007, 17(4):739-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/docetaxel-pediatric-drug-information/abstract-text/17309673/pubmed\" target=\"_blank\" id=\"17309673\">17309673</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mora J, Cruz CO, Parareda A, et al, &quot;Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and Docetaxel,&quot; <i>J Pediatr Hematol Oncol</i>, 2009, 31(10):723-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/docetaxel-pediatric-drug-information/abstract-text/19727011/pubmed\" target=\"_blank\" id=\"19727011\">19727011</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Navid F, Willert JR, McCarville MB, et al, &quot;Combination of Gemcitabine and Docetaxel in the Treatment of Children and Young Adults With Refractory Bone Sarcoma,&quot; <i>Cancer</i>, 2008, 113(2):419-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/docetaxel-pediatric-drug-information/abstract-text/18484657/pubmed\" target=\"_blank\" id=\"18484657\">18484657</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/docetaxel-pediatric-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines. <i>Ann Oncol</i>. 2012;23(Suppl 7):167-173.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/docetaxel-pediatric-drug-information/abstract-text/22997449/pubmed\" target=\"_blank\" id=\"22997449\">22997449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polovich M, Whitford JN, Olsen M. <i>Chemotherapy and Biotherapy Guidelines and Recommendations for Practice</i>. 3rd ed. Pittsburgh, PA: Oncology Nursing Society; 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rapkin L, Qayed M, Brill P, et al. Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. <i>Pediatr Blood Cancer</i>. 2012;59(5):854-858.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/docetaxel-pediatric-drug-information/abstract-text/22302783/pubmed\" target=\"_blank\" id=\"22302783\">22302783</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thiesen J and Kramer I, &ldquo;Physico-Chemical Stability of Docetaxel Premix Solution and Docetaxel Infusion Solutions in PVC Bags and Polyolefine Containers,&rdquo; <i>Pharm World Sci</i>, 1999, 21(3):137-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/docetaxel-pediatric-drug-information/abstract-text/10427584/pubmed\" target=\"_blank\" id=\"10427584\">10427584</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van Hasselt JG, van Calsteren K, Heyns L, et al. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. <i>Ann Oncol</i>. 2014;25(10):2059-2065.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/docetaxel-pediatric-drug-information/abstract-text/24713311/pubmed\" target=\"_blank\" id=\"24713311\">24713311</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zwerdling T, Krailo M, Monteleone P, et al, &quot;Phase II Investigation of Docetaxel in Pediatric Patients With Recurrent Solid Tumors: A Report From the Children's Oncology Group,&quot; <i>Cancer</i>, 2006, 106(8):1821-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/docetaxel-pediatric-drug-information/abstract-text/16532433/pubmed\" target=\"_blank\" id=\"16532433\">16532433</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13011 Version 212.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708706\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F162052\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F162053\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1009498\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1009534\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F162028\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F162014\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F46044272\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1009541\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130975\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F162045\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1009499\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F162103\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F162099\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F162034\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F162018\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F162087\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F162022\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F162024\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F162037\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1009544\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F162017\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F162033\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1009550\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323117\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F2869377\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13011|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">Docetaxel: Drug information</a></li><li><a href=\"topic.htm?path=docetaxel-patient-drug-information\" class=\"drug drug_patient\">Docetaxel: Patient drug information</a></li></ul></div></div>","javascript":null}